A validated silver‐nanoparticle‐enhanced chemiluminescence method for the determination of citalopram in pharmaceutical preparations and human plasma
- 11 June 2013
- journal article
- research article
- Published by Wiley in Luminescence
- Vol. 29 (3) , 266-274
Abstract
A simple and sensitive chemiluminescence (CL) method was developed for the determination of citalopram in pharmaceutical preparations and human plasma. The method is based on the enhancement of the weak CL signal of the luminol–H2O2 system. It was found that the CL signal arising from the reaction between alkaline luminol and H2O2 was greatly increased by the addition of silver nanoparticles in the presence of citalopram. Prepared silver nanoparticles (AgNPs) were characterized by UV–visible spectroscopy and transmission electron microscopy (TEM). Various experimental parameters affecting CL intensity were studied and optimized for the determination of citalopram. Under optimized experimental conditions, CL intensity was found to be proportional to the concentration of citalopram in the range 40–2500 ng/mL, with a correlation coefficient of 0.9997. The limit of detection (LOD) and limit of quantification (LOQ) of the devised method were 3.78 and 12.62 ng/mL, respectively. Furthermore, the developed method was found to have excellent reproducibility with a relative standard deviation (RSD) of 3.65% (n = 7). Potential interference by common excipients was also studied. The method was validated statistically using recovery studies and was successfully applied to the determination of citalopram in the pure form, in pharmaceutical preparations and in spiked human plasma samples. Percentage recoveries were found to range from 97.71 to 101.99% for the pure form, from 97.84 to 102.78% for pharmaceutical preparations and from 95.65 to 100.35% for spiked human plasma. Copyright © 2013 John Wiley & Sons, Ltd.Keywords
This publication has 43 references indexed in Scilit:
- The Pharmacology of Citalopram Enantiomers: The Antagonism by R‐Citalopram on the Effect of S‐Citalopram*Basic & Clinical Pharmacology & Toxicology, 2006
- Simultaneous analysis of citalopram and desmethylcitalopram by liquid chromatography with fluorescence detection after solid-phase extractionClinical Biochemistry, 2005
- Escitalopram versus citalopram: the surprising role of the R-enantiomerPsychopharmacology, 2004
- A High-Performance Liquid Chromatography Method with Photodiode-Array UV Detection for Therapeutic Drug Monitoring of the Nontricyclic Antidepressant DrugsTherapeutic Drug Monitoring, 2003
- Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoringJournal of Chromatography B, 2003
- A REVERSED-PHASE HPLC METHOD DEVELOPMENT FOR THE SEPARATION OF NEW ANTIDEPRESSANTSJournal of Liquid Chromatography & Related Technologies, 2002
- Simplified high-performance liquid chromatographic method for the determination of citalopram and desmethylcitalopram in serum without interference from commonly used psychotropic drugs and their metabolitesJournal of Chromatography B: Biomedical Sciences and Applications, 1996
- Simultaneous determination of citalopram and its metabolites by high-performance liquid chromatography with column switching and fluorescence detection by direct plasma injectionJournal of Chromatography B: Biomedical Sciences and Applications, 1995
- Analysis of Enantiomers of Citalopram and Its Demethylated Metabolites in Plasma of Depressive Patients Using Chiral Reverse-Phase Liquid ChromatographyTherapeutic Drug Monitoring, 1995
- Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopramEuropean Journal of Clinical Pharmacology, 1985